

## NOTIFICATION OF ATTENDANCE AND FORM FOR ADVANCE VOTING

The form must be received by Oncopeptides AB (publ) no later than Friday, 16 May 2025.

The shareholder set out below hereby notifies the company of its participation and exercises its voting right for all of the shareholder's shares in Oncopeptides AB (publ), Reg. No. 556596-6438 at the Annual General Meeting on Thursday, 22 May 2025. The voting right is exercised in accordance with the voting options marked below.

Shareholder	Personal identity number/registration number

**Assurance (if the undersigned is a legal representative of a shareholder who is a legal entity):** I, the undersigned, am a board member, the CEO or a signatory of the shareholder and solemnly declare that I am authorised to submit this advance vote on behalf of the shareholder and that the contents of the advance vote correspond to the shareholder's decisions

**Assurance (if the undersigned represents the shareholder by proxy):** I, the undersigned, solemnly declare that the enclosed power of attorney corresponds to the original and that it has not been revoked

Place and date	
Signature	
Clarification of signature	
Telephone number	E-mail

### Instructions to vote in advance:

- Complete the shareholder information above
- Select the preferred voting options below
- Print, sign and send the form in the original to Oncopeptides AB (publ), Luntmakargatan 46, SE-111 37 Stockholm, Sweden. A completed and signed form may also be submitted by e-mail and shall, in that case, be sent to [lisa.swedel@oncopeptides.com](mailto:lisa.swedel@oncopeptides.com)
- If the shareholder is a natural person who is personally voting in advance, it is the shareholder who should sign under *Signature* above. If the advance vote is submitted by a proxy of the shareholder, it is the proxy who should sign. If the advance vote is submitted by a legal representative of a legal entity, it is the representative who should sign
- A power of attorney shall be enclosed with the form if the shareholder votes in advance by proxy. If the shareholder is a legal entity, a registration certificate or a corresponding document for the legal entity shall be enclosed with the form
- **Please note that a shareholder whose shares are registered in the name of a bank or securities institute must re-register its shares in its own name to vote.** Instructions regarding this are included in the notice convening the meeting

A shareholder cannot give any other instructions than selecting one of the options specified at each item in the form. If a shareholder wishes to abstain from voting in relation to a matter, kindly refrain from selecting an option. A vote (i.e. the advance vote in its entirety) is invalid if the shareholder has provided the form with specific instructions or conditions or if pre-printed text is amended or supplemented. One form per shareholder will be considered. If more than one form is submitted, the form with the latest date will be considered. The form latest received by the company will be considered if two forms are dated at the same date. An incomplete or wrongfully completed form may be discarded without being considered. If a shareholder has voted in advance and attends the Annual General Meeting in person or through a proxy, the advance vote is still valid except to the extent the shareholder participates in a voting procedure at the General Meeting or otherwise withdraws its casted advance vote. If the shareholder chooses to participate in a voting at the General Meeting, the vote cast will replace the advance vote with regard to the relevant item on the agenda.

**Note that the advance vote does not constitute a notification to participate in the General Meeting at the venue in person or through proxy.** Instructions for shareholders who wish to participate in the Annual General Meeting at the venue in person or represented by a proxy are included in the notice convening the Meeting.

The form, together with any enclosed authorisation documentation, shall be received by Oncopeptides no later than **Friday, 16 May 2025**. An advance vote can be withdrawn up to and including **Friday, 16 May 2025**, by contacting Oncopeptides by e-mail to [lisa.swedel@oncopeptides.com](mailto:lisa.swedel@oncopeptides.com) or by post to Oncopeptides AB (publ), Luntmakargatan 46, SE-111 37 Stockholm, Sweden.

For complete proposals regarding the items on the agenda, kindly refer to the notice convening the meeting and the proposals on Oncopeptides' webpage.

For information on how your personal data is processed, see the integrity policy that is available at Euroclear's webpage [www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf](http://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf).

## Annual General Meeting in Oncopeptides AB (publ) on Thursday, 22 May 2025

The voting options below comprise the proposals included in the notice convening the Annual General Meeting and have been provided on the company's website.

<b>2. Election of chairman of the Annual General Meeting</b>
Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>4. Approval of the agenda</b>
Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>6. Determination as to whether the Annual General Meeting has been duly convened</b>
Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>9. Resolutions in respect of</b>
<b>9a. Adoption of the profit and loss statement and balance sheet and the group profit and loss statement and group balance sheet</b>
Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>9b. Allocation of the Company's profit or loss in accordance with the adopted balance sheet</b>
Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>9c. The discharge from liability for the members of the Board of Directors and the CEO</b>
<b>9c. 1. Per Wold-Olsen</b>
Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>9c. 2. Brian Stuglik</b>
Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>9c. 3. Cecilia Daun Wennborg</b>
Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>9c. 4. Per Samuelsson</b>
Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>9c. 5. Jennifer Jackson</b>
Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>9c. 6. Sofia Heigis (CEO)</b>
Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>9c. 7. Jarl Ulf Jungnelius (former member of the Board of Directors)</b>
Yes <input type="checkbox"/> No <input type="checkbox"/>

<b>10. Determination of the number of members of the Board of Directors and the number of auditors to be elected at the Annual General Meeting</b>
<b>10.1 Number of members of the Board of Directors</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>10.2 Number of auditors</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>11. Determination of directors' and auditors' fees</b>
<b>11.1 Directors' fees</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>11.2 Auditors' fees</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>12. Election of members of the Board of Directors and Chairman of the Board of Directors</b>
<b>12a. Per Wold-Olsen, re-election</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>12b. Brian Stuglik, re-election</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>12c. Per Samuelsson, re-election</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>12d. Christine Rankin, new election</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>12e. Chairman of the Board of Directors: Per Wold-Olsen, re-election</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>13. Election of auditor: Öhrlings PricewaterhouseCoopers AB, re-election</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>14. Presentation of the Board of Directors' remuneration report for approval</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>15. Resolution on the introduction of a long-term shareholder program RSU 2025 for members of the Board of Directors</b>
<b>15a. Proposal for resolution on adoption of a long-term shareholder program RSU 2025 for members of the Board of Directors</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>15b. Proposal for resolution on transfer of own ordinary shares to participants in Board RSU 2025</b>

<p>Yes <input type="checkbox"/>    No <input type="checkbox"/></p>
<p><b>15c. Proposal regarding equity swap agreement with a third party</b></p> <p>Yes <input type="checkbox"/>    No <input type="checkbox"/></p>
<p><b>16. Resolution regarding authorisation for the Board of Directors to resolve upon issues of shares, warrants and/or convertibles</b></p>
<p><b>16a. Main proposal</b></p> <p>Yes <input type="checkbox"/>    No <input type="checkbox"/></p>
<p><b>16b. Alternative proposal</b></p> <p>Yes <input type="checkbox"/>    No <input type="checkbox"/></p>